INOVIO Announces Pricing of $17.5 Million Public Offering

INOVIO (Nasdaq: INO) priced an underwritten public offering of 12,500,000 common shares with accompanying Series A and Series B warrants at a combined public offering price of $1.40 per share and warrants, expected to close on or about April 6, 2026.

Rhea-AI Summary

INOVIO (Nasdaq: INO) priced an underwritten public offering of 12,500,000 common shares with accompanying Series A and Series B warrants at a combined public offering price of $1.40 per share and warrants, expected to close on or about April 6, 2026.

The company expects gross proceeds of approximately $17.5 million before discounts, and granted the underwriter a 30-day option to purchase up to 1,875,000 additional shares and warrants. Piper Sandler is sole manager.

Positive

• Gross proceeds of approximately $17.5 million expected
• Underwriter option provides flexibility to raise up to 1,875,000 additional shares
• Shelf registration previously declared effective on January 31, 2024 enables the offering

Negative

• Immediate dilution from issuance of 12,500,000 shares and accompanying warrants
• Potential future dilution if up to 12,500,000 warrants are exercised at $1.40
• Financing priced at $1.40 per share, which may dilute existing holders' ownership percentage

Argus Apr 2 session

-35.06% close to close Open Argus

Details

News Market Reaction – INO

In the Apr 2 session, INO declined 35.06%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -35.1% in the session following this news. A negative reaction despite the added c...

Analysis

The stock dropped -35.1% in the session following this news. A negative reaction despite the added cash fits prior offering-related patterns, where similar financings produced an average move of about -25.59%. The decline reflects investor focus on dilution from new shares and warrants layered onto an already capital-dependent story. Past behavior suggests that repeated reliance on such offerings has weighed on sentiment, raising questions about how quickly the stock can stabilize after funding events.

Key Figures

Gross proceeds: $17.5 million Shares offered: 12,500,000 shares Series A warrants: 12,500,000 warrants +5 more

Gross proceeds

$17.5 million

Expected from this public offering before discounts and expenses

Shares offered

12,500,000 shares

Common stock in the April 2026 underwritten public offering

Series A warrants

12,500,000 warrants

Accompanying Series A warrants in the offering

Series B warrants

12,500,000 warrants

Accompanying Series B warrants in the offering

Exercise price

$1.40 per share

Exercise price for both Series A and Series B warrants

Underwriter option shares

1,875,000 shares

Additional shares in 30-day underwriter option, plus corresponding warrants

Option period

30 days

Duration of underwriter’s option to purchase additional securities

Shares outstanding

68,996,647 shares

Common shares outstanding as of December 31, 2025 (424B5)

Previous Offering Reports

5 past events · Latest: Nov 11

Same Type 5 events

1. Nov 11

   Offering priced

   24h Move

   -7.0%

   Priced $25M stock offering at $1.90 with 30-day underwriter option.

2. Nov 10

   Offering proposed

   24h Move

   -7.0%

   Announced intent to sell common stock with 30-day option for extra shares.

3. Jul 03

   Offering priced

   24h Move

   -37.9%

   Priced $25M offering of shares plus Series A and B warrants at $1.75.

4. Jul 02

   Offering proposed

   24h Move

   -37.9%

   Proposed public offering of common stock and Series A and B warrants.

5. Dec 13

   Offering priced

   24h Move

   -38.3%

   Announced $30M offering at $3.00 with warrants exercisable at $3.76.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, pre-funded warrants, prospectus supplement

3 terms

underwritten public offering financial

"today announced the pricing of an underwritten public offering of 12,500,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"Series A warrants ... (or pre-funded warrants in lieu thereof) at an exercise price"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to and describing"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock and accompanying Series A warrants to purchase up to 12,500,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.40 per share of common stock and Series B warrants to purchase up to 12,500,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.40 per share of common stock, at a combined public offering price of $1.40 per share of common stock and accompanying Series A and Series B warrants. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about April 6, 2026, subject to the satisfaction of customary closing conditions. INOVIO also granted the underwriter an option for a period of 30 days to purchase up to 1,875,000 additional shares of the Company's common stock and Series A warrants to purchase up to 1,875,000 additional shares of its common stock and Series B warrants to purchase up to 1,875,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, excluding any exercise of the underwriter's option to purchase additional securities and assuming no exercise of the accompanying Series A and Series B warrants, are expected to be approximately $17.5 million.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying Series A and Series B warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on November 9, 2023 and declared effective by the SEC on January 31, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-pricing-of-17-5-million-public-offering-302732811.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much capital is INOVIO (INO) raising in the April 2026 public offering?

INOVIO expects to raise approximately $17.5 million in gross proceeds from the offering. According to the company, this figure excludes underwriting discounts, commissions, offering expenses, and any exercise of the underwriter's option.

What securities did INOVIO (INO) include in the April 2, 2026 offering?

The offering includes 12,500,000 common shares and accompanying Series A and Series B warrants. According to the company, pre-funded warrants may be issued in lieu of common shares in certain cases.

What is the exercise price and potential dilution from INOVIO's (INO) warrants?

The Series A and Series B warrants have an exercise price of $1.40 per share. According to the company, exercise of warrants could result in up to 12,500,000 additional shares outstanding, creating potential dilution.

When will the INOVIO (INO) offering close and who is managing it?

The offering is expected to close on or about April 6, 2026, subject to customary closing conditions. According to the company, Piper Sandler is acting as sole manager for the offering.

Does INOVIO (INO) have an option for additional securities in this offering?

Yes. INOVIO granted the underwriter a 30-day option to purchase up to 1,875,000 additional shares and warrants. According to the company, the option is exercisable at the public offering price less underwriting discounts and commissions.

Where can investors find the prospectus for INOVIO's (INO) April 2026 offering?

Investors can access the prospectus and supplement on the SEC website or request copies from Piper Sandler. According to the company, filings are available via the SEC's public EDGAR database.